1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Podcast: Facilitating Patient Monitoring in CAR-T Development

T-cells attacking cancer_1200x675
• Source: Shutterstock

Listen in on the conversation as experts from Cerba Research discuss facilitating patient safety measures in CAR-T therapies by accurately identifying the integration of viral vectors, utilizing flow cytometry, and more.

Listen now as experts discuss answers to:

  • What patient monitoring is required by the FDA?
  • What molecular technology does Cerba Research use and how does it meet FDA requirements?
  • What is the importance of cytometry assays in monitoring CAR-T cells?
  • What are the opportunities for combining flow cytometry with genomic solutions?
  • What key innovations are poised to improve patient monitoring in clinical trials?

Citeline · Podcast: Facilitating Patient Monitoring in CAR-T Development

Open Media

More from Clinical Trials

Pipeline Watch: Eight Approvals And Two Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

The Rise of China Biopharma – Five Themes In 2025

 
• By Andrew McConaghie

The growth of China’s biopharma sector has been perhaps the most significant sector trend this year – Scrip outlines five themes that have emerged during 2025 and in discussions at the recent Jefferies conference in London.

Amycretin Heads For Phase III In Type 2 Diabetes

 
• By Joseph Haas

New Phase II data in type 2 diabetes for Novo Nordisk’s GLP-1/amylin agonist amycretin shows significant weight loss and HbA1c-lowering potential. A Phase III trial is planned.

Kelonia Draws Attention With In Vivo CAR-T Myeloma Data

 
• By Alaric DeArment

The biotech will present data at the upcoming ASH meeting on three patients who achieved PRs or VGPRs with minimal residual disease negativity and no cases of neurotoxicity.

More from R&D

Sponsored by :

Inside The Shift Toward Greener, Faster, Smarter Drug Manufacturing

As pressure mounts to cut costs, reduce environmental impact, and accelerate development, pharmaceutical innovators are rethinking how medicines are made. A new generation of technologies—flow chemistry, biocatalysis, high-throughput experimentation (HTE), and advanced automation—is reshaping the fu

Sponsored by

The British Pharmacopoeia: Setting standards that are trusted worldwide

In this exclusive article with Peter Crowley, Secretary and Scientific Director of the BP Commission, you’ll discover how the BP is preparing for its landmark 2026 edition while strengthening its influence as a global bridge between science, regulation, and industry.

Sponsored by :

Podcast: Beyond The Checkpoint — Next-Gen Strategies In Immuno-Oncology

As the immuno-oncology landscape evolves, developers are facing new challenges in early-phase design, differentiation, and regulatory alignment — all while advancing increasingly complex modalities.

Sponsored by :

Podcast: Innovating Autoimmune Treatment with In Vivo CAR-T

As in vivo CAR-T therapy nears clinical use, researchers and industry leaders explore how it could transform autoimmune disease treatment. Novotech’s Pete Robinson joins Citeline’s Meredith Landry to discuss the science, strategy, and partnerships shaping the future of cell therapy.